UniProtKB/Swiss-Prot Q14444: Variant p.Arg616His

Caprin-1
Gene: CAPRIN1
Feedback?

Variant information Variant position:

616 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

LB/B The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Arginine (R) to Histidine (H) at position 616 (R616H, p.Arg616His). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Change from large size and basic (R) to medium size and polar (H) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Other resources:

Links to websites of interest for the variant.

Variant rs11552285 [ dbSNP | Ensembl ]

Sequence information Variant position:

616 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

709 The length of the canonical sequence.
Location on the sequence:

GFPRSNQPYYNSRGVSRGGS R GARGLMNGYRGPANGFRGGY The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         GFPRSNQPYYNSRGVSR--GGSRGA-RGLMNGYRGPANGFRGGY

Mouse                         GFPRSSQPYYNSRGVSR--GGSRGA-RGLMNGYRGPANGFR

Rat                           GFPRSSQPYYNSRGVSR--GGSRGA-RGLMNGYRGPANGFR

Bovine                        GFPRSNQPYYNSRGVSR--GGSRGA-RGLMNGYRGPANGFR

Drosophila                    NRDRDQ----GGRGDERRNGGDRGNYRSRQYGNSSNTNGRN

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	2 – 709	Caprin-1
Region	524 – 709	Disordered
Modified residue	625 – 625	Phosphotyrosine; by EPHA4
Modified residue	626 – 626	Omega-N-methylarginine
Modified residue	633 – 633	Omega-N-methylarginine
Modified residue	636 – 636	Phosphotyrosine; by EPHA4
Mutagenesis	608 – 608	R -> K. Abolished ability to undergo liquid-liquid phase separation for the formation of a membraneless compartment; when associated with K-612, K-616, K-619, K-626, K-633, K-640, K-660, K-667, K-676, K-684, K-688, K-690, K-695 and K-698.
Mutagenesis	612 – 612	R -> A. Major reduction in MYC and CCND2 RNA-binding; when associated with A-633 and A-690.
Mutagenesis	612 – 612	R -> K. Abolished ability to undergo liquid-liquid phase separation for the formation of a membraneless compartment; when associated with K-608, K-616, K-619, K-626, K-633, K-640, K-660, K-667, K-676, K-684, K-688, K-690, K-695 and K-698.
Mutagenesis	616 – 616	R -> K. Abolished ability to undergo liquid-liquid phase separation for the formation of a membraneless compartment; when associated with K-608, K-612, K-619, K-626, K-633, K-640, K-660, K-667, K-676, K-684, K-688, K-690, K-695 and K-698.
Mutagenesis	619 – 619	R -> K. Abolished ability to undergo liquid-liquid phase separation for the formation of a membraneless compartment; when associated with K-608, K-612, K-616, K-626, K-633, K-640, K-660, K-667, K-676, K-684, K-688, K-690, K-695 and K-698.
Mutagenesis	626 – 626	R -> K. Abolished ability to undergo liquid-liquid phase separation for the formation of a membraneless compartment; when associated with K-608, K-612, K-616, K-619, K-633, K-640, K-660, K-667, K-676, K-684, K-688, K-690, K-695 and K-698.
Mutagenesis	633 – 633	R -> A. Major reduction in MYC and CCND2 RNA-binding; when associated with A-612 and A-690.
Mutagenesis	633 – 633	R -> K. Abolished ability to undergo liquid-liquid phase separation for the formation of a membraneless compartment; when associated with K-608, K-612, K-616, K-619, K-626, K-640, K-660, K-667, K-676, K-684, K-688, K-690, K-695 and K-698.

Literature citations
No reference for the current variant in UniProtKB/Swiss-Prot.

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.